CLAIMS

1. Use of a composition comprising a bacterial strain of the genus *Blautia* in the manufacture of a medicament for reducing the level of *Enterobacteriaceae* in the gastrointestinal tract.

2. The use of claim 1, wherein the *Enterobacteriaceae* is *E. coli*.

3. The use of claim 1 or claim 2, wherein the medicament is for reducing the level of *Enterobacteriaceae* in the gastrointestinal tract in the treatment or prevention of IBS, Crohn's disease, ulcerative colitis, functional dyspepsia, diarrhoea, gastroenteritis, urinary tract infection or neonatal meningitis.

4. The use of claim 1 or claim 2, wherein the medicament is for treating or preventing diarrhoea, gastroenteritis, urinary tract infection or neonatal meningitis.

5. Use of a composition comprising a bacterial strain of the genus *Blautia* in the manufacture of a medicament for the treatment of infections caused by pathogenic *Enterobacteriaceae*.

6. Use of a composition comprising a bacterial strain of the genus *Blautia* in the manufacture of a medicament for the treatment of *E. coli* infection.

7. The use of any one of claims 1-6, wherein the bacterial strain has a 16s rRNA sequence that is at least 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:5 or which has the 16s rRNA sequence of SEQ ID NO:5 or wherein the bacterial strain is *Blautia hydrogenotrophica*.

8. The use of any one of claims 1-6, wherein the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of *Blautia stercoris* or *Blautia wexlerae*; or wherein the bacterial strain is *Blautia stercoris* or *Blautia wexlerae*..

9. The use of claim 1, wherein the composition comprises a bacterial strain of the species *Blautia hydrogenotrophica*, *Blautia stercoris* or *Blautia wexlerae* and wherein the medicament is for reducing the level of *Enterobacteriaceae* in the gastrointestinal tract in a subject diagnosed with IBS.

10. The use of any preceding claim, wherein the medicament is to be administered orally and/or comprises one or more pharmaceutically acceptable excipients or carriers.

11. The use of any preceding claim, wherein the bacterial strain is lyophilised and/or viable.

12. The use of any preceding claim, wherein the composition comprises a single strain of the genus *Blautia* or the *Blautia* bacterial strain as part of a microbial consortium.

13. The use of any preceding claim, wherein the medicament is a food product and/or a vaccine composition.